THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., Feb. 4, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) and Pfizer Inc. (NYSE: PFE) today announced results from a new trial that demonstrated Enbrel® ...

THOUSAND OAKS, Calif. and NEW YORK, May 25, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE) today announced new results from multiple studies of ENBREL, further expanding the ...

SEATTLE, WA – Immunex Corporation (Nasdaq: IMNX) and Wyeth-Ayerst Laboratories, a division of American Home Products (NYSE: AHP) announced today that the U.S. Food and Drug Administration (FDA) has ...

Whether starting or maintaining treatment, the Embark App has multiple features that can help patients on ENBREL throughout their treatment experience. As the healthcare industry continues to evolve ...

SAN FRANCISCO, November 11, 2001– Data from a Phase 2 clinical study of ENBREL® (etanercept) in ankylosing spondylitis will be presented this week at the 65th Annual Scientific Meeting of the American ...

INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. today announced that the US Food and Drug Administration (FDA) has approved ETICOVO™ (etanercept-ykro), a biosimilar referencing ENBREL ® ...

Samsung Bioepis confirmed to Focus via email Friday that the company’s biosimilar to Amgen’s Enbrel (etanercept), to be known as Eticovo (etanercept-ykro), has been approved by the US Food and Drug ...

Please provide your email address to receive an email when new articles are posted on . Approximately 70% of patients with juvenile idiopathic arthritis who are re-treated with etanercept achieve ...

Please provide your email address to receive an email when new articles are posted on . Etanercept and adalimumab are both impactful at improving the health of ...

BEIJING--(BUSINESS WIRE)--Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, today announced that the first ...